Idelalisib
- Generic Name
- Idelalisib
- Brand Names
- Zydelig
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18FN7O
- CAS Number
- 870281-82-6
- Unique Ingredient Identifier
- YG57I8T5M0
- Background
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...
- Indication
用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。
- Associated Conditions
- Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 261
- Registration Number
- NCT01659021
- Locations
- 🇺🇸
Saint Mary's Regional Cancer Center, Grand Junction, Colorado, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸City of Hope, Duarte, California, United States
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 8
- Registration Number
- NCT01644799
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01620216
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
- Conditions
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 416
- Registration Number
- NCT01569295
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇬🇧University College London, London, United Kingdom
🇬🇷G. Genimatas Hospital, Athens, Greece
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT01539512
- Locations
- 🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸UCLA, Santa Monica, California, United States
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 161
- Registration Number
- NCT01539291
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Dorset County Hospital, Dorchester, United Kingdom
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01393106
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT01306643
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 125
- Registration Number
- NCT01282424
- Locations
- 🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸University of Medicine and Dentistry of NJ, New Brunswick, New Jersey, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01203930
- Locations
- 🇺🇸
University of California, San Diego, Moores Cancer Center, La Jolla, California, United States
🇺🇸Columbia University - Herbert Irving Pavilion, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.